Murska Sobota

Researchers are evaluating faricimab in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) affecting at least one eye. The study, called FaReal, aims to assess the effectiveness, safety, clinical insights, and treatment patterns of faricimab in real-world routine clinical practice over a two-year follow-up period. It also seeks to describe and evaluate health economic aspects related to prior anti-VEGF treatments and current faricimab therapy. Faricimab will be given following local clinical practice and labeling guidelines. Patients must have started faricimab treatment at or within three months before signing consent and have received at least one dose in the study eye. The study does not specify fixed dosing schedules but observes real-world use over time. Participants will have data collected on visual acuity and central subfield thickness at baseline and throughout the study. The main outcome measure is the change in visual acuity from the start date to 12 months. Data on treatment safety, clinical practice insights, and health economic factors will also be gathered. The total follow-up period for patients is two years, allowing for long-term monitoring of treatment effects and safety.

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Researchers are investigating the real-world effectiveness of a fixed triple inhaled combination therapy in adults with asthma who remain uncontrolled despite previous treatments. This non-interventional, prospective study focuses on Trimbow 172/5/9 bcg, which combines beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium. While previous randomized trials demonstrated the safety and efficacy of such triple therapies in selected patients, this study aims to assess symptom improvement and treatment adherence in a broader clinical setting over six months. Participants will receive Trimbow 172/5/9 bcg via a pressurized metered-dose inhaler at a recommended dose of two inhalations twice daily. The study includes three visits: enrollment (baseline), one month after enrollment, and six months after enrollment. Patients must have switched to Trimbow no more than one week before or on the day of study inclusion. If treatment changes during the study, patients will be excluded from further participation. During the visits, researchers will collect demographic data, asthma history, lung function, symptom assessments using the Asthma Control Test (ACT), adherence questionnaires, and medication use. The main outcomes measured are improvements in ACT scores and the proportion of patients achieving a clinically important improvement after six months. Secondary outcomes include lung function and treatment adherence. The study plans to enroll 200 patients and expects to complete data collection by June 2026.